Related Experiment Videos
Psychophysical and electrofunctional contrast sensitivity in cataractous patients treated with bendazac-lysine salt
F Ponte1, G Giuffrè, A Cuttitta
1Istituto di Clinica Oculistica, Università di Palermo, Italy.
Abstract:
The clinical progression of the cataract may be influenced by drugs which reduce the denaturation of lens proteins. One of the most promising drugs is the bendazac-lysine salt. The drug was used in a double-blind study of a group of patients with initial cortical cataract in order to evaluate the changes in visual acuity and contrast sensitivity by means of a psychophysical and an electrophysiological method. After 6 months of treatment with bendazac the mean values of visual acuity showed a statistically significant increase in respect to baseline values, as well as an improvement of the threshold of contrast for most spatial frequencies. In the eyes treated with placebo there was no statistical difference between the visual acuity at baseline and after the treatment, but an increase of the contrast threshold for many spatial frequencies. The treatment with bendazac, when compared to the administration of placebo, leads to a statistically significant improvement of the contrast threshold and induces a global improvement on the visual conditions.
Insights
Bendazac-lysine salt improved visual acuity and contrast sensitivity in patients with cortical cataracts. This drug offers a promising therapeutic option for managing cataract progression.
Area of Science:
- Ophthalmology
- Pharmacology
- Biochemistry
Background:
- Cataract progression, characterized by lens protein denaturation, can be influenced by pharmacological agents.
- Bendazac-lysine salt is identified as a potentially effective drug for mitigating cataract development.
Purpose of the Study:
- To evaluate the efficacy of bendazac-lysine salt in improving visual acuity and contrast sensitivity in patients with early cortical cataracts.
- To compare the effects of bendazac-lysine salt with a placebo in a double-blind study setting.
Main Methods:
- A double-blind study was conducted on patients with initial cortical cataracts.
- Psychophysical and electrophysiological methods were employed to assess visual acuity and contrast sensitivity.
- Patients received either bendazac-lysine salt or a placebo for six months.
Main Results:
- Treatment with bendazac-lysine salt resulted in a statistically significant increase in mean visual acuity compared to baseline values.
- Bendazac-lysine salt treatment led to a significant improvement in contrast sensitivity thresholds across most spatial frequencies.
- Placebo treatment showed no significant change in visual acuity, though some increase in contrast thresholds was observed.
Conclusions:
- Bendazac-lysine salt treatment demonstrates a statistically significant improvement in contrast sensitivity compared to placebo.
- The drug induces a global enhancement of visual conditions in patients with early cortical cataracts.
- Bendazac-lysine salt represents a promising therapeutic intervention for managing clinical cataract progression.